Navigation Links
Help for Psoriasis

New research shows the drug efalizumab may reduce symptoms of psoriasis and improve patients’ quality of life.//

Researchers from Loyola University studied more than 550 patients who had psoriasis. Patients received weekly injections of efalizumab (Raptiva) or a placebo for three months. Researchers evaluated the extent of each patient’s condition and rated the degree of scaling and thickness. Patients also completed a questionnaire that measured their quality of life and severity of symptoms.

Results of the study show patients who received efalizumab experienced a significant improvement in their symptoms and quality of life. Patients were considered to have improved if they scored at least 75 percent on the Psoriasis Area and Severity Index. Twenty-seven percent of the patients treated with efalizumab scored at least 75 percent, while only 4 percent of patients in placebo group achieved this score. Patients who took efalizumab also reported a better quality of life than those in the placebo group.

Efalizumab is a biologic drug that blocks immune cells. Researchers say the drug modulates T-cells, which bolster the body’s immune response. Kenneth Gordon, M.D., from the Loyola Psoriasis Center, says, “Biologics are injected, instead of swallowed and block immune cells that produce the dry, flaky skin.”

Psoriasis is triggered by an immune system response that causes skin cells to grow too quickly. The skin cells do not mature normally, and the skin piles up, causing red, scaly lesions to form. About 5 million people in the United States are affected by psoriasis. There is currently no cure, but researchers say new treatments, including biologics, are helping to improve the condition for many patients.

'"/>




Page: 1

Related medicine news :

1. New and unique treatment for Psoriasis patients
2. Comparing Psoriasis Treatments
3. Psoriasis Increases Cancer Risk
4. Managing Patients With Psoriasis
5. Effective Treatment Option For Psoriasis
6. Smoking Aggravates Psoriasis
7. Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder
8. Short-Term Topical Corticosteroid May Offer Relief for Certain Type of Psoriasis
9. Psoriasis raises risk for heart attack
10. Psoriasis Associated With Increased Risk For Heart Attack
11. Remicade Therapy Effective in Treating Severe Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... , ... January 18, 2017 , ... ... Fischell Department of Bioengineering are collaborating on a research project focused on multiple ... the project seeks to use nanotechnology to control the disease without compromising normal ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for ... V, its official endurance training and fundraising team, to compete in the Boston Marathon ... those inspired to finish the world’s oldest annual marathon to join Team V and ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, ... and business owners in central Maryland and the DC region, is inaugurating a charity ... 787,000 people nationally every year, making it the #1 killer in America. However, heart ...
(Date:1/18/2017)... ... January 18, 2017 , ... Dr. Farhan Qureshi is an esteemed dentist who ... modern dental practice has two convenient office locations in Alexandria and Arlington, Virginia. Recently, ... for the Alexandria area. This award confirms the fact that Dr. Qureshi’s patients ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Hear the World Foundation, ... the donation of cochlear implants. In February 2017, the first three children with ... chance of leading an independent life. This engagement builds on the support the ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017 In China ... is where the Upgrade of China,s ... 13th Five-Year Plan for Economic and Social Development of ... Five-Year Plan), and the state council of the ... national strategic emerging industry development plan, identifying medical devices as ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
(Date:1/18/2017)... , Jan. 18, 2017  Robust competition ... rebates and discounts on medicine prices, according to a ... (BRG). The study is among the first to examine ... companies, generic manufacturers, pharmacy benefit managers (PBMs), health plans ... "The BRG study is the first to show what ...
Breaking Medicine Technology: